Editas is based in Cambridge, Massachusetts and has facilities in Boulder, Colorado.. History. With a price/sales ratio of 53.5, Editas Medicine Inc has a higher such ratio than 95.24% of stocks in our set. - Any - 2021 2020 2019 2018 2017 2016 2015. Their stock opened with $16.00 in its Feb 3, 2016 IPO. This book will contain the proceedings of the XIV International Symposium on Retinal Degeneration (RD2010), held July 13-17, 2010, in Mont-Tremblant, Quebec, Canada. [CDATA[>*/ Describes the rise of the media mogul, from his departure from the William Morris Agency in 1975 to form a rival agency--CAA, to his position as the head of Disney in 1995 As for revenue growth, note that EDIT's revenue has grown 148.86% over the past 12 months; that beats the revenue growth of 95.39% of US companies in our set. Which investors participated in the most funding rounds. Found insideThis book will be of interest to molecular biologists, historians, sociologists, and the general reader alike. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. All quotes are in local exchange time. View EDIT: Editas Medicine, Inc.investment & stock information. A popular way to gauge a stock's volatility is its "beta". Log in to see them here or sign up to get started. Found insideIn this classic work, the influential activist and scholar also looks to the future as she examines new developments in gene technology. Get the detailed income statement for Editas Medicine, Inc. (EDIT). Editas Medicine Inc. (EDIT) saw downtrend of -2.23% in the recent trading with $66.73 being its most recent. Ms. Reeve is an accomplished biopharmaceutical executive with more than 25 years of global . A brief financial summary of Editas Medicine Inc as well as the most significant critical numbers from each of its financial reports. /*-->*/. View the latest EDIT financial statements, income statements and financial ratios. Create your Watchlist to save your favorite quotes on Nasdaq.com. Form. Editas Medicine is funded by 17 investors. Filing date. CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that it has appointed Emma Reeve to its Board of Directors. Editas Medicine, Inc. is a genome editing company. Get the latest EDIT: Editas Medicine, Inc. detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.. Something went wrong while loading Watchlist. . [CDATA[/* >